Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$25.15 USD
+0.49 (1.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 342 | 237 | 327 | 306 | 133 |
Receivables | 10 | 0 | 2 | 2 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 6 | 12 | 7 | 6 |
Total Current Assets | 356 | 243 | 341 | 316 | 145 |
Net Property & Equipment | 1 | 2 | 2 | 1 | 2 |
Investments & Advances | 0 | 0 | 0 | 2 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 358 | 248 | 348 | 324 | 155 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 4 | 3 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 25 | 38 | 19 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 2 | 14 | 18 |
Total Current Liabilities | 21 | 31 | 44 | 40 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 24 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 32 | 48 | 45 | 75 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 952 | 753 | 710 | 563 | 298 |
Retained Earnings | -616 | -537 | -409 | -284 | -218 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 337 | 216 | 300 | 280 | 80 |
Total Liabilities & Shareholder's Equity | 358 | 248 | 348 | 324 | 155 |
Total Common Equity | 337 | 216 | 300 | 280 | 80 |
Shares Outstanding | 57.60 | 49.20 | 47.70 | 38.20 | 27.20 |
Book Value Per Share | 5.85 | 4.38 | 6.29 | 7.32 | 2.94 |
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 342 | 321 | 313 | 231 |
Receivables | NA | 10 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 4 | 4 | 5 |
Total Current Assets | NA | 356 | 325 | 317 | 236 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 2 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 358 | 330 | 320 | 240 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 5 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 19 | 25 | 19 | 17 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 21 | 28 | 26 | 23 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 21 | 28 | 26 | 24 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 952 | 945 | 903 | 787 |
Retained Earnings | NA | -616 | -643 | -609 | -570 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 337 | 302 | 294 | 216 |
Total Liabilities & Shareholder's Equity | NA | 358 | 330 | 320 | 240 |
Total Common Equity | 0 | 337 | 302 | 294 | 216 |
Shares Outstanding | 58.20 | 57.60 | 57.60 | 57.20 | 57.20 |
Book Value Per Share | 0.00 | 5.85 | 5.25 | 5.14 | 3.78 |